Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. Best supportive care

Aziz Nazha; Mikkael A. Sekeres; Rami Komrokji; David P. Steensma; Hagop Kantarjian; Gail Roboz; Pierre Fenaux; Thomas Prebet; Nozar Azarnia; Patrick S. Zbyszewski; Steven M. Fruchtman; Valeria Santini; Lewis R. Silverman; Uwe Platzbecker; Guillermo Garcia-Manero

doi:10.1038/s41408-017-0018-7

Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. Best supportive care

Aziz Nazha, Mikkael A. Sekeres, Rami Komrokji, David P. Steensma, Hagop Kantarjian, Gail Roboz, Pierre Fenaux, Thomas Prebet, Nozar Azarnia, Patrick S. Zbyszewski, Steven M. Fruchtman, Valeria Santini, Lewis R. Silverman, Uwe Platzbecker, Guillermo Garcia-Manero

Leukemia

Research output: Contribution to journal › Letter › peer-review

12 Scopus citations

Original language	English (US)
Article number	644
Journal	Blood cancer journal
Volume	7
Issue number	12
DOIs	https://doi.org/10.1038/s41408-017-0018-7
State	Published - Dec 1 2017

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1038/s41408-017-0018-7

Cite this

Nazha, A., Sekeres, M. A., Komrokji, R., Steensma, D. P., Kantarjian, H., Roboz, G., Fenaux, P., Prebet, T., Azarnia, N., Zbyszewski, P. S., Fruchtman, S. M., Santini, V., Silverman, L. R., Platzbecker, U., & Garcia-Manero, G. (2017). Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. Best supportive care. Blood cancer journal, 7(12), Article 644. https://doi.org/10.1038/s41408-017-0018-7

Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. Best supportive care. / Nazha, Aziz; Sekeres, Mikkael A.; Komrokji, Rami et al.
In: Blood cancer journal, Vol. 7, No. 12, 644, 01.12.2017.

Research output: Contribution to journal › Letter › peer-review

Nazha, A, Sekeres, MA, Komrokji, R, Steensma, DP, Kantarjian, H, Roboz, G, Fenaux, P, Prebet, T, Azarnia, N, Zbyszewski, PS, Fruchtman, SM, Santini, V, Silverman, LR, Platzbecker, U & Garcia-Manero, G 2017, 'Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. Best supportive care', Blood cancer journal, vol. 7, no. 12, 644. https://doi.org/10.1038/s41408-017-0018-7

@article{133bfde0ab3d4f82bc20bbecbdb189eb,

title = "Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. Best supportive care",

author = "Aziz Nazha and Sekeres, {Mikkael A.} and Rami Komrokji and Steensma, {David P.} and Hagop Kantarjian and Gail Roboz and Pierre Fenaux and Thomas Prebet and Nozar Azarnia and Zbyszewski, {Patrick S.} and Fruchtman, {Steven M.} and Valeria Santini and Silverman, {Lewis R.} and Uwe Platzbecker and Guillermo Garcia-Manero",

year = "2017",

month = dec,

day = "1",

doi = "10.1038/s41408-017-0018-7",

language = "English (US)",

volume = "7",

journal = "Blood cancer journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "12",

}

TY - JOUR

T1 - Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. Best supportive care

AU - Nazha, Aziz

AU - Sekeres, Mikkael A.

AU - Komrokji, Rami

AU - Steensma, David P.

AU - Kantarjian, Hagop

AU - Roboz, Gail

AU - Fenaux, Pierre

AU - Prebet, Thomas

AU - Azarnia, Nozar

AU - Zbyszewski, Patrick S.

AU - Fruchtman, Steven M.

AU - Santini, Valeria

AU - Silverman, Lewis R.

AU - Platzbecker, Uwe

AU - Garcia-Manero, Guillermo

PY - 2017/12/1

Y1 - 2017/12/1

UR - http://www.scopus.com/inward/record.url?scp=85038437972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038437972&partnerID=8YFLogxK

U2 - 10.1038/s41408-017-0018-7

DO - 10.1038/s41408-017-0018-7

M3 - Letter

C2 - 29238044

AN - SCOPUS:85038437972

SN - 2044-5385

VL - 7

JO - Blood cancer journal

JF - Blood cancer journal

IS - 12

M1 - 644

ER -

Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. Best supportive care

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this